紫杉醇靶向化疗在小细胞肺癌治疗中的疗效及药物相关不良反应分析  

Analysis of the efficacy and drug-related adverse reactions of targeted chemotherapy with paclitaxel in the treatment of small cell lung cancer

作　　者：王冬冬 陈苏蓉 李成光 沈阳 陈亚平 WANG Dongdong;CHEN Surong;LI Chengguang;SHEN Yang;CHEN Yaping(Department of Oncology,Yancheng First Hospital,Yancheng 224000,Jiangsu,China)

机构地区：[1]盐城市第一人民医院肿瘤科

出　　处：《癌症进展》2019年第24期2945-2947,2997,共4页Oncology Progress

摘　　要：目的探究紫杉醇靶向化疗治疗小细胞肺癌的疗效及药物相关不良反应。方法根据治疗方法不同将82例小细胞肺癌患者分为对照组和观察组,各41例。对照组患者接受紫杉醇脂质体化疗,观察组患者接受紫杉醇靶向化疗。比较两组患者的疗效、药物相关不良反应发生情况、生活质量及治疗前后血清肿瘤标志物水平。结果治疗4个疗程后,观察组患者的治疗有效率高于对照组,药物相关不良反应轻于对照组,生活质量评分良好率高于对照组,差异均有统计学意义(P﹤0.05)。治疗2、4个疗程后,两组患者血清中癌胚抗原(CEA)、糖类抗原125(CA125)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)、神经元特异性烯醇化酶(NSE)的表达水平均较本组治疗前降低,且观察组患者血清中CEA、CA125、CYFRA21-1、NSE的表达水平均低于同时间点对照组(P﹤0.05)。结论紫杉醇靶向化疗治疗小细胞肺癌的疗效较好,药物相关不良反应较轻,且可以有效降低血清肿瘤标志物水平,提高患者的生活质量。Objective To investigate the clinical effect and drug-related adverse reactions of targeted chemotherapy with paclitaxel in the treatment of small cell lung cancer(SCLC).Method A total of 82 patients were included in the research and divided in to control group or study group according to the different treatments administered,with 41 patients in each.Patients in control group were treated with liposomal paclitaxel,while those in study group were given targeted chemotherapy with paclitaxel.The efficacy,drug-related adverse reactions,quality of life,as well as the pre-and posttreatment serum tumor markers of the two groups were compared.Result After 4 cycles of treatment,the response rate in study group was higher than that in control group,with lower severity of drug-related adverse reactions and better evaluations of quality of life score observed in study group compared to control group,with statistically significant differences noted(P<0.05).After 2 and 4 cycles of treatment,the expression of serum carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA125),cyto-keratin 19 fragment antigen 21-1(CYFRA21-1),and neuron specific enolase(NSE)were significantly reduced,and the serum CEA,CA125,CYFRA21-1,and NSE were lower than that of control group at the same time(P<0.05).Conclusion Targeted chemotherapy with paclitaxel demonstrates significant efficacy in the treatment of small cell lung cancer,with minor drug-related adverse reactions,and may reduce the level of serum tumor markers,thus improving the quality of life of patients.

关 键 词：紫杉醇 靶向化疗 小细胞肺癌 效果评价 药物相关不良反应 

分 类 号：R734.2[医药卫生—肿瘤]